Fabian Herbst
About Fabian Herbst
Fabian Herbst is the Worldwide Medical Market Lead GI&GU and Women's Cancer at Bristol Myers Squibb and the Founder and Managing Director of Impf2GO - Covid Vaccination Services. He has extensive experience in oncology, having worked at various pharmaceutical companies and launched several key treatments.
Current Roles at Bristol Myers Squibb and Impf2GO
Fabian Herbst holds the title of Worldwide Medical Market Lead GI&GU and Women's Cancer at Bristol Myers Squibb in Boudry, Neuchâtel, Switzerland. Concurrently, he is the Founder and Managing Director of Impf2GO - Covid Vaccination Services based in Berlin, Germany. These roles underscore his versatility and commitment to advancing medical practices both in oncology and public health.
Previous Experience in Medical Leadership
Fabian Herbst's extensive background in medical leadership includes a tenure at GSK as Head Medical Oncology European Mid-Size Markets, and roles at Bristol-Myers Squibb and Celgene as Therapeutic Area Medical Lead for Lymphoma and Solid Tumors. Additionally, he served as Senior Global Medical Director and Global Brand Medical Director at Novartis Oncology. His experience covers a wide array of oncology specialties across multiple top-tier pharmaceutical companies.
Educational Background in Medicine
Fabian Herbst's medical education includes a Medical Degree (Staatsexamen) from the University of Hamburg, completed between 1990 and 1998. Before this, he achieved his High School Diploma from William Chrisman High School in Independence, MO, USA, and from Wirtschaftsgymnasium Hamburg-Harburg, Germany. His educational foundation laid the groundwork for his future contributions to the field of oncology.
Specialization and Expertise in Oncology
Specializing in oncology, Fabian Herbst focuses on breast, ovarian, and gastrointestinal tumors, alongside hematologic malignancies with an emphasis on CAR-T therapy. He is also adept in managing rare diseases like neuroendocrine neoplasia and tuberous sclerosis complex. Notable achievements include the successful launch of key treatments such as Zejula (niraparib) for ovarian cancer, Kadcyla, Herceptin SC for HER2-positive breast cancer, and Afinitor/Votubia (everolimus) for NET and TSC.
Professional Skills and Achievements
Known for his proactive and results-driven approach, Fabian Herbst has conducted numerous advisory boards and built strong relationships with both national and global stakeholders. His record includes repeated loco-regional restructurings and extensive project management experience. His entrepreneurial spirit and willingness to travel extensively for work highlight his dedication to reimagining oncology treatments to improve global health outcomes.